Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, and binding fragments thereof, that bind beta klotho, including human beta klotho, and exemplary specific sequences of their complementarity determining regions, variable regions, heavy chains, and light chains. The present disclosure also provides method of making the antibody or fragment thereof and methods of their use, including, in activating beta-klotho/FGF receptor complex, inducing FGF19-like and/or FGF21-like signaling, improving glucose and lipid metabolism, and treatment of nonalcoholic steatohepatitis.

Abstract: The present disclosure provides binding proteins, such as antibodies and binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use, including in the treatment of nonalcoholic steatohepatitis. The present disclosure also provides exemplary specific sequences of complementarity determining regions, variable regions, heavy chains, and light chains of the antibodies and/or binding fragments thereof.

Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

Abstract: The present disclosure relates to multispecific binding agents, in particular tetravalent bispecific antibodies, related polynucleotides, vectors, host cells, compositions, and methods of producing the binding agents.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.